(Q48109352)
Statements
1 reference
A phase 2 trial of single‐agent bevacizumab given in an every‐3‐week schedule for patients with recurrent high‐grade gliomas (English)
1 reference
A phase 2 trial of single-agent bevacizumab given in an every-3-week schedule for patients with recurrent high-grade gliomas (English)
Sean Grimm
1 reference
Kenji Muro
1 reference
Steven Dubner
1 reference
Jaclyn Renfrow
1 reference
Markus Bredel
1 reference
Jeffrey J. Raizer
Marc C. Chamberlain
M. Kelly Nicholas
James P. Chandler
1 November 2010
1 reference
1 reference
1 reference
116
1 reference
22
1 reference
5297-5305
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference